Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 6/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | STING1 | Q86WV6 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6522395 | 0.97 | PLK1 (0.45) | PLK1PIM1PIM3DYRK1ACAMK2D | |
| SCHEMBL6514615 | 0.94 | PIK3R1 (0.41) | PLK1PIM1PIM3DYRK1ACAMK2D | |
| SCHEMBL6522415 | 0.87 | CHEK1 (0.46) | PLK1PIM1PIM3DYRK1ACNR2 | |
| SCHEMBL6511693 | 0.85 | PIM1 (0.49) | PLK1PIM1PIM3DYRK1ACAMK2D | |
| SCHEMBL6515396 | 0.84 | PIK3R1 (0.39) | PLK1CAMK2DPIK3R1PIK3CA | |
| SCHEMBL6514168 | 0.83 | PLK1 (0.45) | PLK1CNR2STING1CYP3A4CYP2D6 | |
| SCHEMBL6517950 | 0.82 | PIK3R1 (0.41) | PLK1STING1PIK3R1PIK3CA | |
| SCHEMBL6519824 | 0.82 | FAAH (0.44) | PIK3R1PIK3CA | |
| SCHEMBL6507966 | 0.81 | PIM1 (0.45) | PIM1PIM3DYRK1ACAMK2DCNR2 | |
| SCHEMBL6513337 | 0.81 | PIK3R1 (0.45) | DYRK1ACNR2PIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | PLK1 151/4885PIM1 385/4885PIM3 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.